Nemencine
Chubby Chaser
 
Posts: 309
Joined: Jul 2013
Reputation: 88
|
Geo-economics/Stock plays: Isreali/Palestinian conflict
Does anybody have any ideas on stocks(long or short) to play the isreali/palestinian conflict?
Here is an example of what i mean, e.g. (1) china/new zealand botulism problem. (2) winter de-icing salts scarcity stocks play. (3) obamacare rollout stocks play. (4) russian/ukrainian conflict financial market plays.
You get the picture. I like my stock picks to have a catalyst propelling them.
I am looking for something like that for the isreali/palestinian gaza conflict. The current gaza conflict in this case being the stock's catalyst. It doesnt have to be just stocks, are there solid isreali ETFs that i can short? Anybody familiar with EIS and ISRA? dont know much about them.
i am trying to comb through this list to see if there is an isreali defence stocks that i can buy(with emphasis on missile defence companies) or isreali airline stocks that i can short.
Even better, does anybody know isreali companies with strong business exposure to the gaza?(from energy to construction to telecommunication to retail, etc), that is, isreali stocks that does a lot of business in gaza or through gaza?
I should have started this stock operation on isreal since last week, when the conflict just started; but, better late than never....
regards,
Nemencine
.
A year from now you will wish you had started today.....May fortune favours the bold.
(This post was last modified: 07-18-2014 12:57 PM by Nemencine.)
|
|
| 07-18-2014 12:44 PM |
|
The following 1 user Likes Nemencine's post:1 user Likes Nemencine's post
Emancipator
|
Steve9
Chubby Chaser
 
Posts: 282
Joined: Feb 2012
Reputation: 10
|
RE: Stock Market 2014
(07-23-2014 03:15 PM)tarquin Wrote: I have been thinking about a long EXEL play, and there has been a run up in anticipation of the release of this quarter's results. Their cancer drug has reached the Phase III study endpoint goal, but numbers haven't been released. I was under the original belief that they may be released on the 31st, but after reconsideration, I may be wrong. I anticipate you can still scrape a few points before the 31st in anticipation, however.
Long term, I think it happens to be a win. In the past, however, I've bounced from pharm stocks after approval. This has saved me profits (ex. DNDN and ARNA).
Their partner, Roche, will not be releasing the full data set until later this year - no date announced yet.
Roche is filing for regulatory approval this year. It takes the FDA 10 months to review the data for a new drug submission. If it's approved by the FDA, EXEL will co-promote cobimetinib in the USA and receive an equal share of profits or losses on the drug's sales.
I took a small position in EXEL in March after their stock price dropped 50%.
(This post was last modified: 07-23-2014 08:29 PM by Steve9.)
|
|
| 07-23-2014 08:13 PM |
|
The following 1 user Likes Steve9's post:1 user Likes Steve9's post
tarquin
|
tarquin
Chubby Chaser
 
Posts: 565
Joined: Aug 2012
Reputation: 9
|
RE: Stock Market 2014
(07-23-2014 08:13 PM)Steve9 Wrote: (07-23-2014 03:15 PM)tarquin Wrote: I have been thinking about a long EXEL play, and there has been a run up in anticipation of the release of this quarter's results. Their cancer drug has reached the Phase III study endpoint goal, but numbers haven't been released. I was under the original belief that they may be released on the 31st, but after reconsideration, I may be wrong. I anticipate you can still scrape a few points before the 31st in anticipation, however.
Long term, I think it happens to be a win. In the past, however, I've bounced from pharm stocks after approval. This has saved me profits (ex. DNDN and ARNA).
Their partner, Roche, will not be releasing the full data set until later this year - no date announced yet.
Roche is filing for regulatory approval this year. It takes the FDA 10 months to review the data for a new drug submission. If it's approved by the FDA, EXEL will co-promote cobimetinib in the USA and receive an equal share of profits or losses on the drug's sales.
I took a small position in EXEL in March after their stock price dropped 50%.
Thanks. I haven't done my DD yet, but it seems like it's been moving up a bit.
|
|
| 07-23-2014 09:25 PM |
|
|
Steve9
Chubby Chaser
 
Posts: 282
Joined: Feb 2012
Reputation: 10
|
RE: Stock Market 2014
(07-23-2014 09:25 PM)tarquin Wrote: (07-23-2014 08:13 PM)Steve9 Wrote: (07-23-2014 03:15 PM)tarquin Wrote: I have been thinking about a long EXEL play, and there has been a run up in anticipation of the release of this quarter's results. Their cancer drug has reached the Phase III study endpoint goal, but numbers haven't been released. I was under the original belief that they may be released on the 31st, but after reconsideration, I may be wrong. I anticipate you can still scrape a few points before the 31st in anticipation, however.
Long term, I think it happens to be a win. In the past, however, I've bounced from pharm stocks after approval. This has saved me profits (ex. DNDN and ARNA).
Their partner, Roche, will not be releasing the full data set until later this year - no date announced yet.
Roche is filing for regulatory approval this year. It takes the FDA 10 months to review the data for a new drug submission. If it's approved by the FDA, EXEL will co-promote cobimetinib in the USA and receive an equal share of profits or losses on the drug's sales.
I took a small position in EXEL in March after their stock price dropped 50%.
Thanks. I haven't done my DD yet, but it seems like it's been moving up a bit.
EXEL shares up 11% today on 3 times usual volume. News may be leaking or it could be a false rumor.
I found out Roche are planning to present the key data at the European Society for Medical Oncology conference in Madrid 26-30 September 2014.
|
|
| 07-24-2014 07:21 PM |
|
|
Scuba_Instructor
Recovering Beta

Posts: 176
Joined: Jan 2014
Reputation: 5
|
RE: Stock Market 2014
(08-05-2014 02:03 PM)Richiavelli Wrote: Do you mean the ex-date is mid july? Sounds like it hasnt actually been paid out.
Thanks for the reply mate.
The fund in question is the HSBC FTSE 250 tracker (accumulation).
Details from the link below show the ex-div and payment date as follows:
Ex-dividend date:
16 May 2015
Payment date:
15 July 20154
My understanding was that provided I owned the shares before the ex-div date (which I did) then I would be eligible for the payment.
HSBC sent me a message that my fund has earned a small amount, but I've seen no cash payment.
I was expecting this as I opted for accumulation rather than income - but my confusion is stemming from the fact that nothing in my account seems to have changed. No more shares have been bought - so what does the accumulation bit actually mean? Where does my dividend payment go?
I'll go for the income version of the fund next time ... seems far more simple.
Details of fund:
http://www.hl.co.uk/funds/fund-discounts...cumulation
Cheers
SI
|
|
| 08-06-2014 11:59 AM |
|
|
DVY
True Player
    
Posts: 2,109
Joined: Aug 2012
Reputation: 70
|
RE: Stock Market 2014
^^^Yea, but its more popular than ever. I've been all around the world and the McDonalds never ceases to amaze me. They adapt locally and regionally so well. Thailand, Taiwan, Russia, Korea, Japan, Mexico. Its amazing. New menu items and different price-points. In Asia, its open 24 hrs (one of the few), and has free wifi. Tons of students will sit and study there, and occasionally get ice-cream or food. Drunk people come in at 3am, etc etc.
In Thailand, they had lunch specials- fried chicken w/rice. Early morning- gruel. In Korea, they had taro-vanilla mix ice-cream. In Japan, they had different burgers. In Israel, they had burgers named after all the big cities (chicago, miami, NY, LA). McD arches is probably the most well-known consumer brand of all time (coca-cola and pepsi are up there too!).
Beyond that, their economics are fabulous. They receive franchisee fees on gross sales (food costs mean basically zipto McD bottom line). Thats the upside. The downside protection is huge portfolio of mostly US real estate (land +building) that is held at cost- some of which for 30+ years. This doesn't do justice to its balance sheet. Thanks GAAP standards!
WIA- For most of men, our time being masters of our own fate, kings in our own castles is short. Even those of us in the game will eventually succumb to ease of servitude rather than deal with the malaise of solitude
(This post was last modified: 08-14-2014 02:30 AM by DVY.)
|
|
| 08-14-2014 02:28 AM |
|
The following 3 users Like DVY's post:3 users Like DVY's post
Giovonny, Nemencine, Handsome Creepy Eel
|